Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Nov 24, 2021; 12(11): 966-982
Published online Nov 24, 2021. doi: 10.5306/wjco.v12.i11.966
Published online Nov 24, 2021. doi: 10.5306/wjco.v12.i11.966
Modulation of the immune response by heterogeneous monocytes and dendritic cells in lung cancer
Iwona Kwiecień, Elżbieta Rutkowska, Agata Raniszewska, Department of Internal Medicine and Hematology, Laboratory of Hematology and Flow Cytometry, Military Institute of Medicine, Warsaw 04-141, Poland
Piotr Rzepecki, Department of Internal Medicine and Hematology, Military Institute of Medicine, Warsaw 04-141, Poland
Joanna Domagała-Kulawik, Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, Warsaw 02-091, Poland
Author contributions: Kwiecień I, Rutkowska E, and Raniszewska A contributed to reviewing the literature and writing the paper; Rzepecki P contributed to editing the final version of the article to be published; Domagała-Kulawik J contributed to making critical revisions related to important intellectual content of the manuscript.
Supported by Military Institute of Medicine , No. 559 .
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Iwona Kwiecień, MSc, PhD, Research Scientist, Department of Internal Medicine and Hematology, Laboratory of Hematology and Flow Cytometry, Military Institute of Medicine, Szaserów 128 Street, Warsaw 04-141, Poland. ikwiecien@wim.mil.pl
Received: February 26, 2021
Peer-review started: March 2, 2021
First decision: July 27, 2021
Revised: August 2, 2021
Accepted: November 5, 2021
Article in press: November 5, 2021
Published online: November 24, 2021
Processing time: 265 Days and 23.8 Hours
Peer-review started: March 2, 2021
First decision: July 27, 2021
Revised: August 2, 2021
Accepted: November 5, 2021
Article in press: November 5, 2021
Published online: November 24, 2021
Processing time: 265 Days and 23.8 Hours
Core Tip
Core Tip: Monocytes and dendritic cells (DCs) as heterogeneous subpopulations may play a key role in the modulation of the immune response in malignant tumours. Monocytes may have a pro- and anti-tumour function and may differentiate into monocyte-derived DC. DCs have the properties of antigen presenting cells. These cells show a different phenotype depending on their maturity and on the influence of the tumour microenvironment. The DCs are of growing interest for their possible beneficial effects in lung cancer immunotherapy. This review highlights specific DC subpopulations in the anti-tumour response and summarizes the latest ongoing DC clinical trials in lung cancer.